---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-22-028334"
form_type: "8-K"
ticker: null
cik: "0000879682"
company_name: "VIVEVE MEDICAL, INC."
filed_at: "2022-12-02T23:59:59+00:00"
generated_at: "2026-06-21T10:32:46.642735+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Viveve Medical receives Nasdaq delisting notice for bid price and equity non-compliance

## Summary
- Nasdaq Staff notified Viveve on Nov 29, 2022 of delisting for failing Bid Price Rule and Equity Rule.
- Company failed to regain compliance with $1.00 minimum bid price by Nov 28, 2022 grace period end.
- Stockholders' equity as of Sep 30, 2022 fell below $2.5M minimum, triggering second delisting basis.
- Viveve intends to request a hearing before Nasdaq Hearings Panel to stay delisting.
- Plan to regain compliance may include fundraising and reverse stock split, but no assurance of success.

## SEC filing metadata
- accession: 0001437749-22-028334
- form_type: 8-K
- cik: 0000879682
- company_name: VIVEVE MEDICAL, INC.
- filed_at: 2022-12-02T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879682/000143774922028334/0001437749-22-028334-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879682/000143774922028334/vive20221201_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-22-028334
- JSON: https://secwatch.observer/filing/0001437749-22-028334.json
- Plain text: https://secwatch.observer/filing/0001437749-22-028334.txt

## Key facts
- Listing & Compliance Notices
  VIVEVE MEDICAL, INC. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: stockholders equity
  - Rules: 5550(b)(1)
  source text: November 29, 2022, Viveve Medical, Inc. (the “Company”) received notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the Company’s non-compliance with the minimum bid price and stockholders’ equity requirements for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rules 5550(a)(2) (the “Bid Price Rule”) and 5550(b)(1) (the “Equity Rule”), respectively, the Company’s securities were subject to delisting unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Pane
  evidence_url: https://www.sec.gov/Archives/edgar/data/879682/000143774922028334/0001437749-22-028334-index.htm
- Listing & Compliance Notices
  VIVEVE MEDICAL, INC. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: November 29, 2022, Viveve Medical, Inc. (the “Company”) received notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the Company’s non-compliance with the minimum bid price and stockholders’ equity requirements for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rules 5550(a)(2) (the “Bid Price Rule”) and 5550(b)(1) (the “Equity Rule”), respectively, the Company’s securities were subject to delisting unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Pane
  evidence_url: https://www.sec.gov/Archives/edgar/data/879682/000143774922028334/0001437749-22-028334-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.